ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2117

B Cell Phenotype and in Vitro Function in Patients with Rheumatoid Arthritis Developing Low Serum Immunoglobulins after Multiple Cycles of Rituximab

Geraldine Cambridge1, Rita A. Moura2, Venkat Reddy3 and Maria J. Leandro1, 1Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, 2Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, Lisbon, Portugal, 3Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: anti-CCP antibodies, B cells, immune deficiency, rheumatoid arthritis (RA) and rituximab

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: B Cell Biology and Targets in Autoimmune Disease - Poster II: Rheumatoid Arthritis and Other Rheumatic Diseases

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Repeat treatment with rituximab (RTX) predisposes some patients with rheumatoid arthritis (RA) to develop low levels of serum immunoglobulins (Igs). Understanding B cell function in relation to preserving immunity and a sustained clinical response is thus essential. We have investigated the relationships between B cell phenotype and in vitro function in patients RTX-naïve and in those maintaining normal serum Igs (IgM>0.4g/L and IgG>7g/L) or developing low Igs after RTX.

Methods: Serum and peripheral blood mononuclear cells (PBMC) were collected from 56 RA patients (12 pre- and 34 post-RTX). Flow cytometry (% and Mean Fluorescence intensity–MFI) was used to determine naïve and memory B cell subsets (IgD/CD27) and additionally BAFFR, CD32, CD5 and IgM. Post-RTX all patients had evidence of IgD+CD27- naïve B cell reconstitution (>25%) after a period of sustained depletion (<5 CD19+B cells/ml). Serum Igs were analysed in relation to phenotypes, BAFF and soluble CD23 (sCD23; released on differentiation to CD27+ status; normal range 1024-5025pg/ml). PBMC were cultured for 7 days with T cell dependent (TD) (anti-IgM+anti-CD40+IL4+IL21) and T cell independent (TI) (CpG+IL2) stimuli. Classes of Igs, sCD23 and anti-cyclic citrullinated peptides (anti-CCP) were measured in supernatants.

Results: After a median 5 cycles of RTX, 17 patients had normal serum Igs and 17 had developed either low IgM (n=11) or IgG (n=9) or both (n=3). Significant differences between low and normal Igs groups were noted in disease duration (median 25 vs 15 years, p=0.005) and sCD23 levels (median 908 vs 3702pg/ml, p=0.002). Median number and % CD19+B cells, RTX cycles, time from last cycle and serum BAFF were similar. Patients with low Igs also had lower %BAFFR+ pre-switch B cells (IgD+CD27+;p=0.008), higher %CD32B+ switched B cells (IgD-CD27+;p=0.02) and a negative correlation of serum IgM levels and %CD32B+ switched B cells (R2=0.44;p=0.004). In vitro, IgM, IgG or IgA and sCD23 production (normalized for B cell count) was similar between groups. IgM-CCP was only produced after TD and TI stimulus but IgG-CCP was produced spontaneously in all cultures. Significantly higher levels of both IgM- and IgG-CCP antibodies were detected in supernatants from low Ig group.

Conclusion: In patients developing low serum Igs, defective B cell maturation to memory phenotype was suggested by significantly lower levels of serum sCD23. Low serum Igs were also associated with possible reduced BAFFR-mediated anti-apoptotic signaling in IgD+CD27+ B cells and a greater %CD32B+ on memory B cells, resulting in higher thresholds for differentiation to Ig production. In vitro, however, similar amounts of Ig were present in cultures from those with normal or low serum Igs, suggesting a lack of underlying, intrinsic B cell defects. The lack of efficient B cell differentiation in individual patients with low Igs may relate to B cell interactions with immune complexes or with different T cell subsets, possibly resulting from disturbances in RTX-induced germinal centre structure. Our results further suggest increased selection and/or survival properties of autoreactive B cells in patients with low serum total Igs evident in a more robust production of anti-CCP antibodies.


Disclosure: G. Cambridge, None; R. A. Moura, None; V. Reddy, None; M. J. Leandro, None.

To cite this abstract in AMA style:

Cambridge G, Moura RA, Reddy V, Leandro MJ. B Cell Phenotype and in Vitro Function in Patients with Rheumatoid Arthritis Developing Low Serum Immunoglobulins after Multiple Cycles of Rituximab [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/b-cell-phenotype-and-in-vitro-function-in-patients-with-rheumatoid-arthritis-developing-low-serum-immunoglobulins-after-multiple-cycles-of-rituximab/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/b-cell-phenotype-and-in-vitro-function-in-patients-with-rheumatoid-arthritis-developing-low-serum-immunoglobulins-after-multiple-cycles-of-rituximab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology